Full Title
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-5157.
Protocol
26-203
Phase
Phase I (phase 1)
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07213791
ClinicalTrials.gov